Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3
about
P1343
Anaplastic lymphoma kinase: signalling in development and diseaseRole of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesisNucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicityCharacterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsIdentification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivoALK and NSCLC: Targeted therapy with ALK inhibitorsIdentification of a recurrent STRN/ALK fusion in thyroid carcinomasNPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue onlyThe heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitorsNucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3Biological role of anaplastic lymphoma kinase in neuroblastoma.IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK.Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells.ALK Inhibitors, a Pharmaceutical Perspective.Pathobiology of ALK+ anaplastic large-cell lymphoma.The role of molecular pathology in non-small-cell lung carcinoma-now and in the future.Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma.Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactionsAnaplastic lymphoma kinase is dynamically expressed on subsets of motor neurons and in the peripheral nervous system.Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.STAT3 in Cancer-Friend or Foe?Detecting and targetting oncogenic fusion proteins in the genomic era.Anaplastic lymphoma kinase: Role in cancer and therapy perspective.Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs.The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.The role of anaplastic lymphoma kinase in pediatric cancers.Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma.NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL).
P2860
Q24312329-DB21D5F3-F048-4BA5-83BB-9AD667FE4B7BQ24317141-220443D5-53B5-4988-A444-D49B9EAD1A66Q24522838-4CCEB1AE-E947-4174-8761-A4E035FABCC9Q24595848-50247A50-2C5A-469F-873A-A6E4E37927CAQ26769659-64E07D62-1ABD-46F8-BE81-2082813513DAQ28343689-B3473C6F-DA62-4BB7-B1B7-FA2D47859CCCQ28393324-AF9331F8-9523-4911-9E2B-5B9C5E434859Q28539208-76DF4094-580C-4CFC-A8D5-E20EC88C463BQ30831857-C6A381F3-89CB-49E3-A415-FAB5DB43D243Q33924261-816A536B-208E-4D07-BC9B-DF650F402A32Q34162787-FC8E429F-5426-4348-908F-C0BB364B08C6Q34297784-9A2DA888-65C3-4A63-95F7-BFD0BAC29E0BQ34564071-A2EC0C2F-53C2-4DF3-AE8D-DC5A2631156CQ34773094-2067CBC5-6A2B-4CD5-8A67-C7903AB2A0D6Q35084934-3286981F-0B11-4EAF-BF8E-0D8372C24859Q35123227-D3D9843D-8185-4F69-A28C-D9E6BE89C73AQ35849172-984F3D72-92A6-4183-9F60-CD251B9576FCQ35972157-9BABA182-2341-4349-998A-175485BE99A0Q36007756-0D3A7594-876B-4B43-B6A8-F3DCBFC7C3A2Q36040599-4251B1DB-6037-464B-A82E-AC141CB2630EQ36193920-BE3EA64E-6714-4183-9CCE-DADDA5E7C2B5Q36435120-1DFAC7B2-68B0-489E-B15A-7BDC861D03CDQ36935686-524B15B2-84BE-4E95-A482-A31B0086C0CCQ37081609-C4D3D000-9030-439F-B6D4-7624BB216FECQ37271044-55DC4FDE-EEAE-4BBF-BC05-143C5F0702D0Q37411178-724BAE1E-BE1D-414B-92EE-089EEB125934Q38101044-FFE54A9E-575A-404F-8FFB-679497693343Q38226313-C6405668-290C-472C-8B21-47F272681112Q38336067-458259EE-3BF6-4B80-8376-002BA211E425Q38623421-FD0AA812-AB37-41A7-9713-138E42CBB57CQ38962008-E15219C8-1BE0-43DF-85EA-28A31AFC67D2Q41116766-704D7B20-9F67-4213-8CA0-5364E705C67CQ41148199-2F400E88-5EAB-4583-A8B8-42DD64B7ADE7Q41844175-81BBEAA2-F69C-4182-8E95-CC3E03A605FCQ41916862-757439B4-FA1C-4D22-8D91-EBB4D2273062Q42254184-E7BFE5F6-BCD2-4DD9-B7AF-A24113D3BE87Q42315727-8FD78CC7-AD6F-4532-9429-BE336990AE86Q45840997-50660C82-45A3-42E2-8B9A-4E1D9F8A6390Q47134648-F2464A18-533F-4F53-AD49-FC94EBDE5A06Q47895445-6620E071-A105-495D-B5AC-339E2B599457
P2860
Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Hyperphosphorylation of a nove ...... Ki-1 lymphoma cell line, AMS3
@ast
Hyperphosphorylation of a nove ...... Ki-1 lymphoma cell line, AMS3
@en
Hyperphosphorylation of a nove ...... Ki-1 lymphoma cell line, AMS3
@nl
type
label
Hyperphosphorylation of a nove ...... Ki-1 lymphoma cell line, AMS3
@ast
Hyperphosphorylation of a nove ...... Ki-1 lymphoma cell line, AMS3
@en
Hyperphosphorylation of a nove ...... Ki-1 lymphoma cell line, AMS3
@nl
prefLabel
Hyperphosphorylation of a nove ...... Ki-1 lymphoma cell line, AMS3
@ast
Hyperphosphorylation of a nove ...... Ki-1 lymphoma cell line, AMS3
@en
Hyperphosphorylation of a nove ...... Ki-1 lymphoma cell line, AMS3
@nl
P2093
P3181
P1433
P1476
Hyperphosphorylation of a nove ...... Ki-1 lymphoma cell line, AMS3
@en
P2093
P304
P3181
P407
P4510
P577
1994-06-01T00:00:00Z